Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanna Finocchiaro

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Neoplasia (New York, N.Y.)|October 2, 2009
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesAntonio Marchetti, Michele Milella, Lara Felicioni, et al.
Cancer Discovery|March 11, 2025
RORγ bridges cancer-driven lipid dysmetabolism and myeloid immunosuppressionAugusto Bleve, Martina Incerti, Francesca Maria Consonni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patientsFederico Cappuzzo, Antonio Marchetti, Margaret Skokan, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapyArmando Santoro, Lorenza Rimassa, Alberto F Sobrero, et al.
Cancers|September 28, 2019
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with GefitinibRiziero Esposito Abate, Raffaella Pasquale, Alessandra Sacco, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancerFederico Cappuzzo, Alessandro Morabito, Nicola Normanno, et al.
Critical Reviews in Oncology/Hematology|February 2, 2024
Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approachGiovanni Luca Ceresoli, Giulio Rossi, Francesco Agustoni, et al.
Clinical Lung Cancer|June 28, 2020
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective StudyAndrea Luciani, Antonio Marra, Luca Toschi, et al.
British Journal of Cancer|November 1, 2018
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutationsFrancesco Passiglia, Federico Cappuzzo, Oscar Alabiso, et al.
Journal for Immunotherapy of Cancer|March 19, 2025
Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse eventsAgnese Losurdo, Cristina Panico, Chiara Catalano, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Neoplasia (New York, N.Y.)|October 2, 2009
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesAntonio Marchetti, Michele Milella, Lara Felicioni, et al.
Cancer Discovery|March 11, 2025
RORγ bridges cancer-driven lipid dysmetabolism and myeloid immunosuppressionAugusto Bleve, Martina Incerti, Francesca Maria Consonni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patientsFederico Cappuzzo, Antonio Marchetti, Margaret Skokan, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapyArmando Santoro, Lorenza Rimassa, Alberto F Sobrero, et al.
Cancers|September 28, 2019
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with GefitinibRiziero Esposito Abate, Raffaella Pasquale, Alessandra Sacco, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancerFederico Cappuzzo, Alessandro Morabito, Nicola Normanno, et al.
Critical Reviews in Oncology/Hematology|February 2, 2024
Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approachGiovanni Luca Ceresoli, Giulio Rossi, Francesco Agustoni, et al.
Clinical Lung Cancer|June 28, 2020
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective StudyAndrea Luciani, Antonio Marra, Luca Toschi, et al.
British Journal of Cancer|November 1, 2018
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutationsFrancesco Passiglia, Federico Cappuzzo, Oscar Alabiso, et al.
Journal for Immunotherapy of Cancer|March 19, 2025
Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse eventsAgnese Losurdo, Cristina Panico, Chiara Catalano, et al.
Pageof 5